Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Company Overview

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Key Stats

• Today's Range: $8.37 to $8.37
• 50-Day Range: $8.33 to $8.40
• 52-Week Range: $2.66 to $8.55
• Volume: N/A
• Average Volume: 2.97 million shs
• Market Capitalization: $401.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNCE Stock Analysis - Frequently Asked Questions

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNCE
• CIK: 1367920
• Web: www.concertpharma.com
• Phone: (781) 860-0045
• Fax: 302-636-5454
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.05 million
• Net Margins: N/A
• Pretax Margin: -300,735.69%
• Return on Equity: -109.43%
• Return on Assets: -76.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.03
• Quick Ratio: 9.03

Sales & Book Value

• Annual Sales: $32.58 million
• Price / Sales: 12.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.24 per share
• Price / Book: 2.58

Miscellaneous

• Outstanding Shares: 47,940,000
• Free Float: 42,507,000
• Market Cap: $401.26 million
• Optionable: Optionable
• Beta: 0.52